Thermo Fisher Scientific Release: Next-Generation Media System Provides The Highest In Vitro Survival Of Neurons

Published: Sep 25, 2017

- Gibco B-27 Plus Neuronal Culture System overcomes common neurobiology research challenge

CARLSBAD, Calif., Sept. 25, 2017 /PRNewswire/ -- A newly launched media system by Thermo Fisher Scientific has been designed to enable reliable and biologically relevant in vitro neuronal cell models by increasing survival of neurons by more than 50 percent compared to conventional products. The new Gibco B-27 Plus Neuronal Culture System, comprised of B-27 Plus Supplement and Neurobasal Plus Medium, allows neurobiology researchers to replace current neuronal cell culture supplements and basal media to maximize survival of neurons in short and long term cultures without having to change workflows.

 (PRNewsfoto/Thermo Fisher Scientific Inc.)

Since 1993, the Gibco B-27 Supplement and Neurobasal Medium has been the trusted standard for a variety of neuronal culture applications, with citations in more than 11,000 publications. Recent enhancements to the Gibco B-27 Plus Neuronal Culture System provide an advanced formulation, an upgraded manufacturing process, and stringent quality control measures to reliably maximize survival and health of neurons in vitro.

"Cultured neurons have been used for decades as models to study development and disease. However, neurons are extremely sensitive and consistently obtaining viable cells can be extremely difficult," said Amy Butler, vice president and general manager of Cell Biology at Thermo Fisher Scientific. "We optimized the Gibco B-27 Plus Neuronal Culture System to provide the highest survival of neurons, which should save time culturing neurons and allow more time to advance research."

Available in the same formats that customers have relied on for years, the B-27 Plus Neuronal Culture System includes both the 50X, 10 mL B-27 Plus Supplement and the 500 mL Neurobasal Plus Medium and can seamlessly replace previous neuronal cell culture systems, including the original B-27 Supplement and Neurobasal Medium. The Gibco B-27 Plus Neuronal Culture System and the Gibco CultureOne Supplement, which launched last November is designed to optimize neural stem cell differentiation into neurons and are the latest additions to Thermo Fisher's neurobiology product portfolio.

For researchers who are either maintaining primary rodent and human pluripotent stem cell (PSC)-derived neurons or differentiating human PSC-derived neural stem cells to neurons, the combination of the Gibco B-27 Plus Supplement, the Neurobasal Plus Medium, and the CultureOne Supplement removes the challenges of culturing neurons and enables an improved downstream experience.

The Gibco B-27 Plus Neuronal Culture System and Gibco CultureOne Supplement are for research use only.

For more information on Gibco B-27 Plus Neuronal Culture System, visit www.thermofisher.com/b27plus.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information:

Mauricio Minotta
Thermo Fisher Scientific
+1 760 929 2456
Mauricio.Minotta@thermofisher.com

or

Maurissa Messier
CG Life
+1 908 208 9254
Mmessier@cglife.com

View original content with multimedia:http://www.prnewswire.com/news-releases/next-generation-media-system-provides-the-highest-in-vitro-survival-of-neurons-300524660.html

SOURCE Thermo Fisher Scientific Inc.

Back to news